WPD Pharmaceuticals Board of Directors Approved the Raise of WPD Poland's Share Capital
WPD Pharmaceuticals Board of Directors Approved the Raise of WPD Poland's Share Capital
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2022) - WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the "Company" or "WPD") a clinical-stage pharmaceutical company announces that the Company's Board of Directors (the "Board") has approved the raise of WPD Pharmaceuticals Sp. z o.o. ("WPD Poland"), the Polish subsidiary of the Company share capital from PLN 400,000 to PLN 2,100,000, that is by the amount of PLN 1,700,000, by establishment of 34,000 new, equal and indivisible shares of the nominal value of PLN 50 each and the total nominal value of PLN 1,700,000. Raise of WPD Poland's share capital is the second step of a plan to restructure WPD Poland, which the company announced on February 9, 2022.
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年9月20日)-WPD製藥公司公司(CSE：WBIO)(FSE：8SV1)(The“公司”或“WPD”)一家臨牀階段的製藥公司宣佈，公司董事會(“董事會”)已批准WPD PharmPharmticals Sp.ZO.O。(“WPD波蘭”)，公司的波蘭子公司通過設立34,000股新的、平等和不可分割的股份，將股本從400,000茲羅提增加到2,100,000茲羅提，即1,700,000茲羅提，每股面值50茲羅提，總面值1,700,000茲羅提。WPD波蘭公司2022年2月9日宣佈的重組計劃的第二步是籌集WPD波蘭的股本。
According to the above on September 14, 2022, WPD Poland's Shareholders' Meeting has approved a share capital from PLN 400,000 to PLN 2,100,000. The new shares will be subscribed and taken-up by biotech investor by December 31, 2022. The long-term plans of the company include obtaining capital from the Polish capital market and listing of WPD Polska on the Warsaw Stock Exchange. The implementation of this plan depends on developments in the capital market in Europe.
如上所述，2022年9月14日，WPD波蘭公司的股東大會批准了從40萬茲羅提到210萬茲羅提的股本。新股將於2022年12月31日前由生物技術投資者認購和認購。該公司的長期計劃包括從波蘭資本市場獲得資本，以及WPD Polska在華沙證券交易所上市。這一計劃的實施取決於歐洲資本市場的發展。
About WPD Pharmaceuticals
關於WPD製藥公司
WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 9 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.
WPD是一家生物技術研發公司，專注於腫瘤學和病毒學，即研究和開發涉及生物化合物和小分子的醫藥產品。WPD已經在某些國家批准了9種新藥候選藥物，其中4種處於臨牀開發階段。這些候選藥物是在醫療機構進行研究的，WPD目前正在與維克森林大學以及波蘭的領先醫院和學術中心進行合作。
WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes about 29 countries in Europe and Asia, including Russia, depending on the compound.
WPD與維克森林大學健康科學公司簽訂了許可協議，並分別與Moleclin Biotech，Inc.和CNS PharmPharmticals，Inc.簽訂了分許可協議，每一項協議都向WPD授予許可方的某些技術的獨家、承擔版税的分許可。這些協議為WPD提供了某些研究、開發、製造和銷售等權利。CNS製藥和Moleclin Biotech的再許可領域包括歐洲和亞洲的大約29個國家，包括俄羅斯，具體取決於化合物。
On Behalf of the Board
我謹代表董事會
'Mariusz Olejniczak'
‘Mariusz OlejNiczak’
Mariusz Olejniczak
CEO, WDP Pharmaceuticals
馬裏烏茲·奧列尼扎克
WDP製藥公司首席執行官
Contact:
聯繫方式：
Investor Relations
Email: investors@wpdpharmaceuticals.com
Tel: 604-428-7050
投資者關係
電子郵件：Investors@wpdPharmPharmticals.com
電話：604-428-7050
Web:
網頁：
Cautionary Statements:
警示聲明：
Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所和加拿大投資行業監管組織均不對本新聞稿的充分性或準確性承擔責任。
This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company anticipates will or may occur in the future, that WPD would significantly benefit from advancement of Berubicin as a treatment for GBM. Forward-looking statements in this press release include that WPD's drugs could be developed into novel treatments for cancer. These forward-looking statements reflect the Company's current expectations based on information currently available to management and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those projected. Factors which may prevent the forward looking statement from being realized is that the drug compounds may not provide the benefits expected and we may not develop them further; competitors or others may successfully challenge a granted patent and the patent could be rendered void; that we are unable to raise sufficient funding for our research; that we may not meet the requirements to receive the grants awarded; that our drugs don't provide positive treatment, or if they do, the side effects are damaging; competitors may develop better or cheaper drugs; and we may be unable to obtain regulatory approval for any drugs we develop. The Company assumes no obligation to update them except as required by applicable law.
本新聞稿包含前瞻性陳述。前瞻性陳述是對公司預期未來將會或可能發生的活動、事件或發展的陳述，這些活動、事件或發展將從貝魯比星作為治療GBM的方法的進步中顯著受益。本新聞稿中的前瞻性陳述包括WPD的藥物可能被開發成癌症的新療法。這些前瞻性陳述反映了基於管理層目前掌握的信息的公司目前的預期，並受到許多風險和不確定因素的影響，這些風險和不確定因素可能會導致結果與預期的大不相同。可能阻礙前瞻性陳述實現的因素是，藥物化合物可能無法提供預期的益處，我們可能無法進一步開發它們；競爭對手或其他人可能成功挑戰已授予的專利，專利可能被宣佈無效；我們無法為我們的研究籌集足夠的資金；我們可能無法滿足獲得授予的贈款的要求；我們的藥物不能提供積極的治療，或者如果提供了，副作用是破壞性的；競爭對手可能會開發出更好或更便宜的藥物；以及我們開發的任何藥物可能無法獲得監管部門的批准。除適用法律要求外，本公司不承擔更新它們的義務。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。